...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis.
【24h】

Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis.

机译:经导管动脉化学栓塞与微球栓塞治疗无法切除的肝细胞癌的比较:一项荟萃分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Survival of patients with surgically unresectable hepatocellular carcinoma (HCC) is very poor due to the limited effective treatments available. Transhepatic arterial chemoembolization (TACE) and microsphere embolization may offer hope for such patients; however, to date, their efficacy has not been evaluated. This study was designed to compare the effectiveness of these two treatments for patients with unresectable HCC.This meta-analysis searched literature using various databases and revealed 13 studies on surgically unresectable HCC patients treated with TACE or microsphere embolization. Response rate, 1-year survival, overall survival, and time to progression were then analyzed and compared.These thirteen studies included 597 and 1,233 patients with unresectable HCC for microsphere embolization and chemoembolization treatments, respectively. The data showed that microsphere embolization therapy was significantly better for longer overall survival, 1-year survival, longer time to progression, and complete or partial response rate than that of chemoembolization treatment.These data demonstrated that microsphere embolization treatment of patients with surgically unresectable HCC provided much better survival and treatment response than that of TACE.
机译:由于可用的有限有效治疗方法,无法手术切除的肝细胞癌(HCC)患者的生存率非常低。经肝动脉化疗栓塞(TACE)和微球栓塞可能为此类患者提供希望;然而,迄今为止,它们的功效尚未得到评估。这项研究旨在比较这两种疗法对无法切除的HCC患者的疗效。这项荟萃分析使用各种数据库检索了文献,并揭示了13项关于通过TACE或微球栓塞治疗无法手术切除的HCC患者的研究。然后分析和比较缓解率,1年生存率,总生存率和进展时间。这13项研究分别包括597例和1,233例不可切除的HCC患者,进行微球栓塞和化学栓塞治疗。数据显示,微球栓塞治疗比化学栓塞治疗具有更好的总体生存期,1年生存率,更长的进展时间以及完全或部分缓解率。这些数据表明,对于无法手术切除的HCC患者,微球栓塞治疗提供了比TACE更好的生存和治疗反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号